Rozprawy doktorskie: „Breast – Cancer – Genetic aspects”

1

Chiu, Yuk-tim, i 趙玉甜. "Sirtuin 6 expression in breast cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48541254.

Pełny tekst źródła

Streszczenie:

Sirtuins (Silent Information Regulator Two (SIR2) protein) are NAD-dependent protein deacetylases, originally discovered in yeast. Sirtuins play a critical role in the regulation of different cellular processes involving aging, chromatin silencing and cellular differentiation. SIRT6 is a member of Sirtuins and plays a role in regulation of DNA repair and suppression of genomic instability. Many studies have shown SIRT6 to be associated with diseases of aging, including cancer. The finding by our collaborator that SIRT6 expression was found in chemotherapy-resistant breast cancer cell lines stimulated this study which aims to explore the role of SIRT6 expression as a prognostic marker in breast cancer. One hundred and eighteen breast cancer samples in tissue microarray blocks were examined for SIRT6 expression by immunohistochemistry. As SIRT6 expression is predominantly located in the nucleus but with a small fraction in cytoplasm, the calculation of nuclear or cytoplasmic localization scores were divided by total localization scores to increase accuracy. The nuclear localization scores represent the SIRT6 expression in breast cancer. Statistical analysis was performed using SPSS software. SIRT6 overexpression in the nucleus was significantly associated with poorer overall survivals (p=0.018) while low cytoplasmic expression of SIRT6 was also associated with poorer overall survivals (p=0.014). There was no relationship between SIRT6 expression and disease-specific survivals. By multivariate analysis, SIRT6 expression was an independent predicator of poorer overall survivals. These results suggest that SIRT6 overexpression induces apoptosis in cancer cells through deacetylation of transcription factor p65. SIRT6 interacts with and deacetylates p65 to activate nuclear factor kappa B gene linked to cancer. Also high levels of SIRT6 were associated with resistance to paclitaxel and epirubicin inMCF-7 breast cancer cell lines. This provides evidence that Sirt6 is an important prognostic marker and therapeutic target for breast cancer.
published_or_final_version
Pathology
Master
Master of Medical Sciences

Style APA, Harvard, Vancouver, ISO itp.

2

Lau, Tsz-kwan, i 劉子筠. "The expression of RIP140 in breast cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/193544.

Pełny tekst źródła

Streszczenie:

Breast cancer is the most common cancer in females worldwide. RIP140 was one of the first proteins recognized as nuclear receptor transcriptional cofactor which interacts with several nuclear receptors. RIP140 plays a central role in metabolic tissues with multifunctional co-regulation. It is an essential protein required for energy homeostasis and mammary gland development. RIP140 has been found to be involved in development of breast cancer in response to estrogen. RIP140 is recruited by estrogen receptors in the presence of estrogen. Increasing levels of estrogen and RIP140 stimulate their transcription and regulate proliferation and differentiation of mammary glands. We hypothesize that RIP140 may be over expressed in breast cancer and may be correlated with clinicopathological features and may thus serve as a possible new prognostic marker in breast cancer. In our study, the correlation between the RIP140 expression and survival was investigated by immunohistochemistry (IHC), and analyzed by Pearson’s chi-square and Kaplan Meier analysis. Cox regression analysis was performed to examine the relationship between clinic-pathological parameters and the survival. Total of one hundred and eighteen breast cancer samples were examined for the RIP140 staining localization in breast cancer cells. Our results showed that the IHC staining of RIP140 was observed in both cytoplasm and nucleus of breast cancer cells. The ER positive staining was significantly correlated with high nuclear expression of RIP140, but not RIP140 cytoplasmic expression. Thus nuclear RIP140 expression was examined for correlation with other clinic-pathological features and patient survival. The correlation between nuclear RIP140 expression and clinic-pathological features by Pearson’s chi-square test showed that high RIP140 nuclear staining score is associated with ER positive status (p-value=0.041) and tumor stage (p-value=0.008). Kaplan Meier test shown that nuclear RIP140 expression is not significant associated with either overall survival or disease-specific survival. However, a trend of high nuclear RIP140 score was observed with poorer overall and disease-specific survival though not statistically significant. To conclude, our results suggest RIP140 is not a useful prognostic marker for breast cancer. Further investigation with larger sample size is necessary to improve the statistical significance of the test.
published_or_final_version
Pathology
Master
Master of Medical Sciences

Style APA, Harvard, Vancouver, ISO itp.

3

Wong, Yim-han, i 黃艷嫺. "Expression of sirtuin 1 in breast cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/193549.

Pełny tekst źródła

Streszczenie:

Breast cancer is the most frequent malignancy in women. Recent studies have proposed that sirtuin 1 (SIRT1) may play a certain role in the tumorgenesis and disease progression of cancer. Therefore, in this study, we demonstrate the localization of SIRT1 in the breast cancer cells by immunohistochemistry method and try to correlate the expression level of SIRT1 with various clinical-pathological parameters as well as the survival time of breast cancer patients. One hundred and eighteen breast cancer cases, arrayed as dual‐cores, were studied in the tissue microarray blocks for their SIRT1 nuclear and cytoplasmic stain. The expression of SIRT1 is found in over 95% of the tumor samples. Although the active functioning site of SIRT1 is known to be mainly the nucleus, both nuclear and cytoplasmic localization score are assessed separately for SIRT1 expression for more accurate statistically analysis. By bi‐variate Pearson correlation analysis, high nuclear localization of SIRT1 is significantly correlated with low tumor grade (p=0.006) and ER (p=0.001) and PR positive status (p=0.044). Moreover, the cytoplasmic localization score of SIRT1 shows positive correlation with tumor grade (p=0.010). The relationship of SIRT1 expression and survival time of breast cancer patient was studied by Kaplan‐Meier analysis. Despite a marginal fail in obtaining a statistically significant result, the trend in survival curve clearly indicated that nuclear localization of SIRT1 is associated with a poorer overall survival (p=0.052). Although the pathway of how SIRT1 affects the survival of breast cancer patient is still unknown, many studies suggested that it is largely due to the deacetylated inactivation of p53 tumor suppressor protein by SIRT1. In conclusion, we propose that nuclear localization of SIRT1 can be a potential prognostic factor of breast cancer patients.
published_or_final_version
Pathology
Master
Master of Medical Sciences

Style APA, Harvard, Vancouver, ISO itp.

4

Flach, Susanne. "Structural variation of the genome in breast cancer". Thesis, University of Cambridge, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.648565.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

Cheng, Wan-biu, i 鄭雲標. "Genetic analysis on the EPHB2 gene in breast cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2005. http://hub.hku.hk/bib/B45009946.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Wu, Lai-han, i 胡麗嫻. "Expression of FOXO3a in breast cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2007. http://hub.hku.hk/bib/B45011515.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Webster, Lucy R. "Diagnostic molecular profiling of ductal carcinoma in situ of the breast". Thesis, The University of Sydney, 2007. https://hdl.handle.net/2123/28109.

Pełny tekst źródła

Streszczenie:

The introduction of population-based mammographic screening has led to a dramatic increase in the diagnosis of ductal carcinoma in situ (DCIS) of the breast; with DCIS now accounting for approximately 25-35% of all screen-detected breast cancers. Epidemiological, histopathological and molecular studies have provided compelling evidence to support the notion that DCIS is a direct precursor of invasive cancer; although such data also indicate that DCIS represents a highly heterogeneous group of lesions. Some women with DCIS will develop life-threatening invasive cancer, whereas others may not. Currently, determination of the malignant potential of an individual DCIS lesion is very difficult, making selection of optimal treatment from the range of options available challenging. Histopathology has long been used to classify invasive breast tumours into biologically relevant sub-classes; although for DCIS there is still no universally accepted histological grading system. In recent years, gene expression profiling of invasive breast cancer has demonstrated that superior classification, prognostication and prediction can be achieved. Therefore, the principal aim of this study was to use classic histopathology and contemporary molecular biological methods to better classify DCIS lesions according to their inherent malignant potential. A significant difficulty in studying in situ breast cancer is a lack of rational endpoints against which potential markers can be judged; consequently initial studies were directed at identifying a rational surrogate end-point for use in subsequent molecular studies. Through the examination of a large cohort of screen-detected breast cancers, we demonstrated that the grade of concomitant invasive breast cancer was the best surrogate end-point to examine the malignant potential of in situ disease due to its direct relationship with breast cancer biology and established correlation with breast cancer survival. Another significant limitation to molecular studies of DCIS is the heterogeneity of breast tissue and the small size and limited extent of in situ lesions. Therefore, in this thesis laser capture microdissection and nucleic acid amplification techniques were successfully optimised and applied to a well-characterised cohort of DCIS lesions and adjacent areas of pre-malignant and benign epithelium. Gene expression profiling analysis of this cohort of laser capture microdissected samples was successfully performed on 36K oligonucleotide microarrays. Supervised analysis was used to identify genes differentially expressed between DCIS lesions associated with grade 1 and grade 3 invasive cancer. The “DCIS discriminative gene list” comprised 173 oligonucleotide probes and according to the relative expression of the top 100 genes samples were clustered into two biologically relevant groups. In addition, a gene expression grade index (GGI) was calculated and using a defined cut-point the DCIS lesions were classified into the same “low” and “high” molecular grade groups that had highly significant correlations with histopathologic and biological factors including DCIS nuclear grade, cell polarisation, necrosis, ER, PR, HERZ, p53 and Ki67. Further support for the clinical relevance of the gene expression derived DCIS classification was provided by the strong correlation between the molecular grade groups and both disease-free and overall survival in two independent invasive breast cancer cohorts. lmportantly, work described in this thesis also demonstrated that the gene-expression derived classification can be closely approximated using a combination of routinely available features including DCIS nuclear grade and accurate Ki67 scoring of the in situ component; thus offering a novel, biologically significant and clinically useful DCIS classification system. Results from array-based comparative genomic hybridisation (aCGH) analyses further supported the biological relevance of the gene-expression derived classification and identified potential candidate chromosomal regions underlying the variable malignant potential of in situ breast cancer.

Style APA, Harvard, Vancouver, ISO itp.

8

Khoo, Ui-soon, i 邱瑋璇. "Genetic susceptibility to gynaecological cancers in the Chinese population". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2002. http://hub.hku.hk/bib/B25257365.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

陳遠光 i Yuen-kwong Chan. "Study on the role of genetic and epigenetic factors in relation to theBRCA genes in epithelial ovarian cancers". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2002. http://hub.hku.hk/bib/B42576726.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

馮敬業 i King-yip Fung. "Screening of recurrent BRCA gene mutations in Chinese breast and ovarian cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2000. http://hub.hku.hk/bib/B31969720.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Iddawela, Mahesh Yasantha Bandara. "Genome wide copy number and gene expression profiling using archived tissue for molecular marker studies in breast cancer". Thesis, University of Cambridge, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.609626.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

Tang, Kei-shuen, i 鄧紀旋. "Role of BRCA1 in stress-induced autophagy in breast and ovarian cancercells". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B45847204.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

Michailidou, Kyriaki. "Statistical analyses of genome-wide association studies in breast cancer". Thesis, University of Cambridge, 2015. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.708642.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

Agenbag, Gloudi. "Molecular genetic analysis of familial breast cancer in South Africa". Thesis, Link to the online version, 2005. http://hdl.handle.net/10019/953.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Cheuk, Tin-hoi, i 卓殿凱. "CXCR4 and FOXO3a expression in breast cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46632360.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Lesniak, Karen. "Psychological and Sociodemographic Predictors of Psychological Distress in BRCA1 and BRCA2 Genetic Testing Participants within a Community Based Genetic Screening Program". Thesis, University of North Texas, 2000. https://digital.library.unt.edu/ark:/67531/metadc2565/.

Pełny tekst źródła

Streszczenie:

Mutations in BRCA1 and BRCA2, the first two breast cancer susceptibility genes identified, carry as much as an 85% lifetime risk of developing breast, ovarian or other cancers. Genetic testing for mutations in these two genes has recently become commercially available. There have been varying amounts of psychological distress noted among women with a family history of breast cancer. Distress has been observed to impact psychological functioning, activities of daily living, and the practice of breast cancer surveillance behaviors. Within the genetic screening process, psychological distress has been shown to impact the decision to undergo genetic screening, the comprehension and retention of risk assessment information, as well as affecting the subject following the receipt of the genetic test results. Little work has been done to examine predictors of distress within at risk subjects. This study examines psychological distress among 52 community women presenting for BRCA1 and BRCA2 genetic mutation testing. Predictors of distress included family cancer history, education, age, Ashkenazi ethnicity, and Internality and Powerful Others Health Locus of Control. Vulnerable sub-groups of patients include younger women, women with higher levels of education and women of Ashkenazi ethnicity.

Style APA, Harvard, Vancouver, ISO itp.

17

Wu, Pei Hsin, i 吳佩欣. "The expression of transcription factors TWIST and Snail in breast cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B47468907.

Pełny tekst źródła

Streszczenie:

Breast cancer comprises of 22.9% of all cancers worldwide in females. In the year 2008, it has caused 458,503 deaths worldwide. De-regulation of transcription factors has been shown to play an important role in the progression of breast cancers. Snail and TWIST genes have been found to promote epithelial-mesenchymal transition (EMT). It has been suggested that the level of expression of each of these genes correlates with poor prognosis in different types of solid tumors. For breast cancer, the up-regulation of Snail was associated with recurrence and higher tumor grade, while the up-regulation and up-regulation of TWIST was associated with shorter survival and metastatic development. However, in recent studies conflicting results have been observed. Our collaborator had analyzed mRNA expression data obtained from the Gene Expression Omnibus (GEO) database together with patient survival data from the breast cancer cohort datasets, and found that expression of Snail when stratified against TWIST expression levels or vice versa, gave more significant association with survival than when expression levels of Snail or TWIST was considered on their own. To investigate whether these findings could be demonstrated at a protein level, we performed imrnuno-histochemisty analysis on breast cancer samples in tissue microarray blocks. Nuclear and cytoplasmic scores of TWIST were successfully assessed separately in 114 invasive breast cancer patients. The Snail scores were obtained from previous studies. As Snail and TWIST are both transcription factors, nuclear expression of each was examined for correlation of Snail and TWIST with pathological features and patient survival. Our results showed that nuclear Snail expression did not correlate with survival (p=0.498) but when stratified with nuclear TWIST, high levels of nuclear Snail expression associated with poorer survival in patients with low nuclear TWIST expression (p=O.2l2), though not statistically significant which agreed with the mRNA results of our collaborator. For nuclear TWIST expression, association with survival was in reverse from that of the mRNA findings. Low expression levels of TWIST mRNA was associated with shorter survival, however immuno-histochemistry showed that high levels of nuclear TWIST expression marginally correlated with poorer survival (p=O.079). Low levels of cytoplasmic TWIST expression on the other hand, correlated with poorer survival in patients (p=O.024), and when stratified against high nuclear Snail, expression was associated with shorter survival (p=O.022), which is in keeping with mRNA findings. The results show that Snail and TWIST expression gave more prognostic value when considered together than when considered individually, which suggests that Snail and TWIST might be functionally similar in the promoting of EMT mediated breast. It also highlights the importance of nuclear and cytoplasmic localization by immuno-histochemistry in evaluating results and in assessing its role in promoting breast cancer progression. In conclusion Snail and TWIST should be considered together for prognostication of breast cancer as they may complement each other in predicting the progression of the disease.
published_or_final_version
Pathology
Master
Master of Medical Sciences

Style APA, Harvard, Vancouver, ISO itp.

18

Harrison, Hannah. "Oestrogen and Notch Signalling in the Regulation of Human Breast cancer Initiating cells". Thesis, University of Manchester, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.492869.

Pełny tekst źródła

Streszczenie:

The transition from normal mammary development to the formation of aberrant cancerous tissues requires numerous mutations to occur. These alterations allow cancer cells to evade the usually strictly controlled pathways of survival, proliferation and self-renewal. The cell of origin for most tumours remains unknown but evidence that a sub-population of stem-like cells, termed cancer initiating cells, exists within solid cancers is strong.

Style APA, Harvard, Vancouver, ISO itp.

19

Wade, Walsh Margo. "Women Receiving Genetic Counseling for Breast Cancer Risk: Cancer Worry, Psychological Distress, and Risk Recall Accuracy". Thesis, University of North Texas, 1999. https://digital.library.unt.edu/ark:/67531/metadc2185/.

Pełny tekst źródła

Streszczenie:

This follows an earlier study of the same data set, which, through its findings, presented new questions that are investigated in this study. Both studies used a prospective controlled design, wherein women receiving genetic counseling for breast cancer risk were randomized into two groups. Subjects receiving an audiotaped recording of their genetic consultation (tape group) were compared to subjects who also had a genetic consultation but did not receive an audiotaped recording of it (no-tape group). Participants were drawn from attendees at the genetic clinics of two London hospitals and included 115 women with a family history of breast cancer. Cancer worry and psychological distress were assessed before genetic consultation (baseline), and at one- and six-month follow-ups by post. Objective risk was estimated by the geneticist during the consultation, and subjective risk was assessed at one month follow-up. The goals of the current study were to investigate relationships between cancer worry, psychological distress, and recall of genetic risk for breast cancer in a sample of women receiving genetic counseling for breast cancer risk, and to investigate the role sociodemographic variables on cancer worry, psychological distress, or risk recall for these women. Results for this sample of women with a family history of breast cancer found that there were consistent relationships between cancer worry, psychological distress, objective risk, and subjective risk before and after genetic consultation. This suggests that women=s psychological responses are appropriate to their level of cancer risk. There were no differences found between the tape and no-tape groups for objective or subjective risk, or for nearness of recall accuracy or degree of under-/over-estimation. Provision of an audiotaped recording of the genetic consultation did not appear to enhance recall of risk information. The role of sociodemographic variables on the psychological and risk variables assessed in this study was very minor. Age was mildly correlated with cancer worry, and employment was predictive of cancer worry only at baseline.

Style APA, Harvard, Vancouver, ISO itp.

20

Li, Shao Ying. "Study of the role of DNA methylation and PIK3CA mutations in human breast cancer". University of Western Australia. School of Surgery and Pathology, 2006. http://theses.library.uwa.edu.au/adt-WU2006.0031.

Pełny tekst źródła

Streszczenie:

[Truncated abstract] Introduction: Breast cancer is a heterogeneous disease, resulting in very different outcomes for women with apparently similar tumour characteristics. In order for patients to have optimal treatment, a better understanding of the molecular nature of their disease is required. Aims: The aims of this thesis were: 1) To determine whether methylation of RARβ2, ER, CDH1, BRCA1, CCND2, p16 and TWIST genes are associated with phenotypic features of breast cancer and the prognostic significance of methylation of these genes. 2) To investigate for possible associations between the frequency of methylation at RARβ2, CDH1, ER, BRCA1, CCND2, p16 and TWIST genes and the presence of germ-line variants in the TS, MTHFR, MS, CBS, MTHFD1 and DNMT3B genes, as well as for possible correlations between these polymorphisms and clincopathological features of breast cancer including patient outcome. 3) To determine whether PIK3CA mutations determined clinical phenotype and the prognostic significance of PIK3CA mutations in a large and well characterized cohort of breast cancer patients. Methods: A large and well characterized series of primary breast tumours were selected for methylation of RARβ2, ER, CDH1, BRCA1, CCND2, p16 and TWIST genes using MSP, and for polymorphisms in TS, MTHFR, MS, CBS, MTHFD1 and DNMT3B genes using PCR, PCR-RFLP and PCR-SSCP. Mutations to PIK3CA were detected using F-SSCP. Results and Conclusions: Methylation frequencies ranged from 11% for CCND2 to 84% for ER. More frequent hypermethylation was observed in tumours with poor histological differentiation compared to those with well/moderate differentiation, as well as trends for association with larger tumour size and mutant TP53. Tumours with ER and CDH1 methylation were associated with significantly lower hormone receptor levels, younger age at diagnosis and the presence of mutant p53. TWIST methylation is firstly reported to be associated with significantly older patient age at diagnosis and larger tumour size. Our data suggests that gene methylation may be linked to various pathological features of breast cancer. However, there appears to be little support for a distinctive CpG island methylator phenotype in breast cancer.

Style APA, Harvard, Vancouver, ISO itp.

21

Ting, Kam-po, i 丁金寶. "Study of minichromosome-maintenance-deficient 4 (MCM4) gene in breast cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B4357211X.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

Kwong, Ava, i 鄺靄慧. "Phenotypic and genotypic epidemiological studies of Hong Kong Chinese patients with hereditary breast cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hub.hku.hk/bib/B50534002.

Pełny tekst źródła

Streszczenie:

Breast cancer is the most common cancer in women in most part of the world. Although there are multiple risk factors which have been reported to be related to breast factors, by far one of the highest risk of breast cancer is the inheritance of the BRCA1 and BRCA2 cancer susceptibility genes. The lifetime risk of breast cancer can be as high as 60-80% for BRCA mutation carriers. As the breast cancer epidemiology and genetic predisposition is increasingly understood, it transpires that ethnic differences exist. Although variations of genetic factors may play a role, the reasons for these differences remain unclear. Most published data are Caucasian based and there are limited publications on hereditary breast cancer in Asians available to date. This thesis hypothesizes that due to the known differences in genetic predisposition in different ethnic groups, it is likely that the mutation spectrum of BRCA mutations and breast cancer characteristics of Hong Kong Chinese, a relatively unexplored cohort, will differ to that of Caucasians. Moreover, the ancestors of local Hong Kong population migrated from Mainland China of which majority were from Southern China. They then remained in Hong Kong and populated and hence similar to smaller countries such as Iceland and Poland where founder mutations are identified, it is likely that a founder mutation will be present. Lastly due to different cultural differences and availability of screening facilities, management options of those found to carry the BRCA mutation may differ to that of other countries. The aims of this study are as follows 1) Perform a comprehensive genetic and phenotypic analysis using Full Gene Sequencing and Multiplex ligation-dependent probe amplification (MLPA) testing of Hong Kong Chinese cohort or breast cancer patients/families who are clinically high risk and to develop a registry to collect data related to this study. 2) To identify the spectrum of BRCA mutation in Hong Kong. 3) To report, any novel mutations, founder mutations, large rearrangements and deletions (using MLPA) if any are found. 4) If founder mutations are present, to develop a fasting and cheaper technique so that rapid screening can be offered. 5) To identify the choice of management in this high risk cohort. A total of 451 clinically high-risk breast and /or ovarian cancer patients from 1 March 2007 to 28 February 2011 were recruited. Based on sequencing results, 59 (13.1%) deleterious BRCA gene mutations were identified: 24 (41%) were in BRCA1 and 35 (59%) in BRCA2. Of the 59 deleterious mutations, 22 (37%) were novel mutations, 8 were BRCA1 and 14 were BRCA2 mutations. Eight recurrent mutations were identified of which four were proven to be founder mutations. These results showed that both BRCA1 and BRCA2 mutations account for a substantial proportion of hereditary breast/ovarian cancer in Sothern Chinese population. By using MLPA, four patients with large genomic rearrangement were identified and one of whom has a de novo BRCA1 mutation encompassing exons 1 to 12 deletion. Such mutations are rare and this de novo mutation has not been previously reported. Moreover another novel BRCA2 variant of unknown significance (c.7806-9T>G), a splice-site intronic mutation, was recharacterized to be pathogenic due to clinical suspicion based on its co-segregation. High Resolution Melting Technique in performing rapid screening for the founder mutations was developed and tested on a further cohort confirming the possibility of the use of founder mutations screening technique in future. Finally, concerning the management choice of BRCA mutation carriers undertaken in Chinese, BRCA mutation carriers in our cohort are more likely to choose intensive surveillance as an option of risk management rather than prophylactic interventions. In summary, this study provides valuable information on mutation spectrum of BRCA1 and BRCA2 in Southern Chinese population. Identifications founder mutations and knowledge of its prevalence in this Chinese population provides important information both to genetic counselling and risk assessment as well as to development of a cost-effective screening strategy. Furthermore, our study on the choice of management of mutation carriers allows us to have a baseline for development of future studies of psychological impact of genetic testing and management related to genetic testing, so that these high risk families can be better supported.
published_or_final_version
Surgery
Doctoral
Doctor of Philosophy

Style APA, Harvard, Vancouver, ISO itp.

23

Zhu, Li, i 朱麗. "Determination of predictive markers related to micro-metastasis in breast cancer patients". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B30330919.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

Tse, Yuk-ting Edith, i 謝玉婷. "Estrogen receptor gene polymorphisms and breast cancer risk in the Chinese population". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B38709466.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Elliott, Diana. "The impact of genetic counselling for familial breast cancer on women's psychological distress, risk perception and understanding of BRCA testing". University of Western Australia. School of Population Health, 2008. http://theses.library.uwa.edu.au/adt-WU2008.0190.

Pełny tekst źródła

Streszczenie:

[Truncated abstract] Background: A review of the literature indicated there was a need for more long-term randomised controlled studies on the effects of BRCA counselling/testing on high risk women, including improved strategies for risk communication. Reviews have also shown women are confused about the significance of inconclusive or non informative results with a need for more research in this area. Aims: The general aim of this study was to evaluate the impact of breast cancer genetic counselling on psychological distress levels, perception of risk, genetic knowledge and understanding of BRCA testing/test results in a cohort of 207 women from high risk breast cancer families who were referred for genetic counselling in Perth during the period 1997 to 2001. Short- and long-term impact of BRCA genetic counselling/testing was determined in women with and without cancer in a randomised controlled trial as part of which women were randomised to either receive immediate versus delayed genetic counselling. This included family communication patterns before BRCA testing, anticipated outcomes of testing on oneself and family including intentions for result disclosure. Comprehension of index and predictive BRCA testing with possible results was assessed both in the short- and the long-term and understanding of individual or family BRCA test results was evaluated at long-term. The effect of genetic counselling on breast cancer risk perception in unaffected women was evaluated. This study considered a theoretical framework of educational learning theories to provide a basis for risk communication with possible relevance for future research. ... Only 25% of the original study population (52/207) reported BRCA results and women's understanding of results is concerning. Key findings were: 1. The majority of affected women received an inconclusive result. 2. Out of twelve unaffected women who reported results, seven were inconclusive which are not congruent with predictive testing. This implies that these women did not understand their test result. 3. A minority of untested relatives did not know whether a family mutation had or had not been found in their tested family member or what their actual test result was. This implies either a lack of disclosure or that woman did not understand the rationale for and significance of testing for a family mutation. 4. Three relatives did not understand a positive result was a mutation. Conclusion: The implication of this research for breast cancer counselling and testing services is that women who wait for counselling are no worse off in terms of short- or long-term general psychological distress than women who receive the intervention early. There is a suggestion that unaffected women without the disease found counselling more advantageous than affected women. The meaning of BRCA results as reported by women is concerning particularly women's understanding of negative and inconclusive results and further research is needed in this area. Too much information presented at counselling may affect women's comprehension of risk, BRCA testing and future test results and further research is required to evaluate the effects of information overload.

Style APA, Harvard, Vancouver, ISO itp.

26

Loh, Yet Hua. "Diet, MGMT and SMAD7 gene variants and breast, prostate and colorectal cancer risk : results from the EPIC-Norfolk study". Thesis, University of Cambridge, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.608981.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

27

Wong, Janice, i 黃正而. "Genetic polymorphism of BRCA2 minor variant in breast cancer of Hong Kong Chinese population". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48541874.

Pełny tekst źródła

Streszczenie:

Breast cancer is the leading malignancy among Asian women, which often have a young disease onset pattern. Germline mutation in high-penetrance breast cancer susceptibility genes are known to play an important role in early disease onset, but only 5-10% cases are associated with mutations in BRCA1 or BRCA2 gene. By contrast, common variants might also have deleterious effect in breast cancer development. A BRCA2 coding SNP rs1799944 (N991D) was found to have no association with breast cancer risk among Hong Kong Chinese population, but significantly confers a better disease-free survival in the breast cancer patients. In this study, the relevance of this association was further verified by using an enlarged sample pool of Hong Kong Chinese breast cancer patients. A total of 483 Hong Kong Chinese breast cancer subjects were unselectively recruited between 1976 and 2011. SNP N991D genotype of patients was determined by Taqman allelic discrimination genotyping assay. Pearson’s Chi-Square and logistic regression were used to assess the association between the SNP genotypes and breast cancer disease characteristics. Kaplan-Meier survival and multivariate Cox proportional hazards regression analyses were used to examine the relationship between the SNP genotypes and overall survival as well as disease-specific survival of the patients. Of the 449 breast cancer patients successfully genotyped, 16.9% had heterozygous AG genotype and 0.4% had rare homozygotes GG genotype. The variant allele G had a MAF of 8.91% among Hong Kong Chinese breast cancer patients. Patients harboring the SNP N991D variant allele G had longer disease-free survival period compared to the non-carriers (HR = 0.28; 95% CI: 0.09 – 0.92; p=0.036), which was confounded by patients’ local and/or distant metastasis status at diagnosis stage (HR=3.00; 95% CI: 1.57 – 5.74; p=0.001). Although N991D carriers also had a better overall survival pattern than the non-carriers, the difference between them was not statistically significant. Moreover, the association of SNP N991D variant allele G carriers with a lower disease recurrence rate (OR= 0.27; 95% CI: 0.82 - 0.90; p=0.023) was owing to the association of the variant with fewer distant metastases (OR = 0.11; 95% CI: 0.02 – 0.83; p=0.010) but not the local relapse status (OR= 0.38; 95% CI: 0.85 – 1.67; p=0.182) of the clinical outcome when comparing to the non-carriers. In conclusion, the missense BRCA2 N991D SNP has indicated an association with better clinical outcome as well as disease-free survival in Hong Kong Chinese breast cancers.
published_or_final_version
Pathology
Master
Master of Medical Sciences

Style APA, Harvard, Vancouver, ISO itp.

28

胡夕春 i Xichun Hu. "Study on the use of potential prognostic parameters in breast cancer patients". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2001. http://hub.hku.hk/bib/B30158138.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

29

Lau, Lai-yee, i 劉麗儀. "Identification of microRNAs associated with tamoxifen resistance in breast cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B47235792.

Pełny tekst źródła

Streszczenie:

Tamoxifen is the most widely used endocrine therapy for both early and advanced estrogen receptor (ER) positive breast cancer patients. About half of the patients that initially respond to the antiestrogen become estrogen-independent and ultimately develop resistance to the treatment. The precise molecular mechanisms of tamoxifen resistance remain poorly understood. Dysregulation of microRNAs (miRNAs) has been frequently reported in breast cancer and linked to cancer development, progression and therapeutic response. To gain a more comprehensive picture of the miRNA regulatory network for modulating tamoxifen responsiveness, we examined global expression profiles of more than 600 miRNAs in a matched pair of tamoxifen-sensitive ZR75 and tamoxifen-resistant AK47 breast cancer cell lines using TaqMan Low Density Array (Applied Biosystems). Under 4-hydroxytamoxifen treatment, 102 miRNAs displayed differential responses between the sensitive cells and the resistant cells. At basal levels, upregulation of 32 miRNAs and downregulation of 75 miRNAs were observed in the resistant cells as compared to the sensitive cells. Among the 9 miRNAs of significant differential expression selected for validation, expression profiles of the 7 miRNAs could be reproduced. Of these, 4-hydroxytamoxifen treatment greatly increased miR-449a/b expression in sensitive ZR75 cells, whereas miR-449a/b expression was significantly reduced in resistant AK47 cells at basal levels, which was further confirmed in a panel of tamoxifen-resistant breast cancer cell lines. Such downregulation of miR-449a/b in the resistant cells was partially attributed to DNA methylation-mediated repression of miR-449a/b. Notably, miR-449a/b expression exhibited a significant positive correlation with ER-α status (miR-449a: P=0.006, miR-449b: P=0.013) and progesterone receptor (PR) status (miR-449a: P=0.010, miR-449b: P=0.021), and a prominent inverse association with tumor grade in 61 breast cancer tissues (miR-449a: P=0.001; miR-449b: P=0.009). Also, breast cancer patients with high miR-449a/b expression tended to have increased disease-free survival (miR-449a: P=0.019; miR-449b: P=0.117). To further support the tumor suppressor function of miR-449, stable miR-449b overexpression in the resistant cells reduced cell proliferation. More intriguingly, restoring miR-449b expression increased sensitivity to 4-hydroxytamoxifen-induced apoptosis via suppression of AKT activity without restoring ER-α expression. In contrast, miR-449a/b knockdown reduced ER-α and PR expression, but enhanced phosphorylation of AKT, extracellular signal-regulated kinase- 1/2 (ERK1/2), c-Jun N-terminal kinases (JNK) and also ER-α at serine 167 and serine 118 residues. Furthermore, we demonstrated c-Myc is a target gene of miR-449 as confirmed by bioinformatics and experimental analyses. Computational algorithms predicted a highly conserved miR-449a/b binding site within C-MYC 3’untranslated region (3’UTR). Compared to the parental sensitive cells, c-Myc was overexpressed in the resistant cells. Forced expression of miR-449b suppressed c-Myc protein level. To further support the notion that c-Myc is a direct target of miR-449, interactions between miR-449b and C-MYC 3’UTR were confirmed by co-expression of miR-449b and c-Myc expression constructs and luciferase reporter assay. Taken together, our data strongly suggest the critical role of miR-449 in modulating altering response to tamoxifen via targeting c-Myc. Suppression of miR-449 repressed genomic ER action and concomitantly activated non-genomic ER pathways. These findings may provide insights to improve breast cancer management and open a wide avenue for therapeutic interventions for overcoming tamoxifen resistance.
published_or_final_version
Pathology
Doctoral
Doctor of Philosophy

Style APA, Harvard, Vancouver, ISO itp.

30

Leung, Wai Ching-wa Gina, i 衛靜華. "The influence of flutamide, tamoxifen and dietary fat on hormone-induced mammary carcinogenesis". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2002. http://hub.hku.hk/bib/B42576830.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

31

Chen, Jie, i 陈洁. "The role of FOXO3a in the development of chemoresistance in breast cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B47234519.

Pełny tekst źródła

Streszczenie:

Breast cancer is the most common malignancy in women and represents one of the major causes of death worldwide. The PI3K-Akt-FOXO3a signalling pathway has been shown to play a crucial role in tumorigenesis and the development of drug resistance in many cancer types. However, previous studies on FOXO3a using breast cancer tissues were controversial. So this study aims at better understanding of the role of FOXO3a in the development of drug resistance, especially endocrine resistance and anthracycline resistance in breast cancer. Examination of FOXO3a and phosphorylated-Akt (P-Akt) expressions in breast cancer tissue microarrays revealed nuclear FOXO3a was significantly associated with poor prognosis (p=0.014) and lymph node positivity (p=0.052) in invasive ductal carcinoma. Using the tamoxifen and anthracycline-sensitive and -resistant breast cancer cell lines as models, we found that the nuclear accumulation of FOXO3a was associated with enhanced anthracycline-resistance but not tamoxifen-resistance. This was consistent with the finding that sustained nuclear FOXO3a was associated with poor prognosis, as cytotoxic chemotherapy resistance is linked to limited therapeutic options and poor prognosis. We demonstrated a possible feedback mechanism in which induction of FOXO3a activity in the anthracycline-sensitive MCF-7 cells induced Akt phosphorylation and promoted cell proliferation arrest. Using MDA-MB-231-FOXO3a(A3):ER cells in which FOXO3a activity could be induced by 4-hydroxytamoxifen, we showed that FOXO3a induction could up-regulate PI3K-Akt activity but had little effect on cell proliferation, which indicates impaired Akt-FOXO3a axis in chemoresistant cell models. To further uncover the precise mechanism of Akt-FOXO3a deregulation in the development of chemoresistance, we have explored the post-translational regulation of FOXO3a by miRNAs. Through a series of Gain-and-Loss functional experiments and luciferase reporter assays in vitro, three miRNAs, including miR-222, miR-221 and miR-29a, were found to suppress FOXO3a protein expression through binding directly to FOXO3a 3’UTR. Moreover, the aberrant expressions of the miR-222/221 cluster and miR-29a in drug resistant cell lines could confer a proliferation advantage to cancer cells through suppressing FOXO3a expression. We further demonstrated that FOXO3a as a transcription factor could transactivate the oncogenic miR-222 and miR-221 expressions under certain chemotherapy stimulation. This suggests the existence of a feedback regulatory loop composed of the miR-222/221 cluster and FOXO3a which may not only play a self-protective role under drug treatment in chemosensitive cells, but also partially explain the tolerated nuclear FOXO3a in the breast cancer with poor prognosis. Taken together, our study suggested that lymph node metastasis and poor survival in invasive ductal breast carcinoma are linked to an uncoupling of the Akt-FOXO3a signalling axis, as in these breast cancers the nuclear-located FOXO3a was unable to induce cell death or cell cycle arrest. We also demonstrated post-translational regulation of FOXO3a by miR-222/221 and miR-29a, while aberrant expressions of miR-222/221 and miR-29a may promote cell resistance to therapy through directly suppressing FOXO3a. FOXO3a could further contribute to the deregulation of the miR-222/221 cluster as a transcription factor in breast cancer. Studying this Akt-FOXO3a-miRNAs signalling circuit will provide us better understanding in predicting and monitoring treatment response in breast cancer and other malignancies.
published_or_final_version
Pathology
Doctoral
Doctor of Philosophy

Style APA, Harvard, Vancouver, ISO itp.

32

Hamdi, Yosr. "Evaluation of the association between common genetic variants and breast cancer risk". Doctoral thesis, Université Laval, 2017. http://hdl.handle.net/20.500.11794/28384.

Pełny tekst źródła

Streszczenie:

Le cancer du sein est la néoplasie la plus fréquente chez la femme. Un ensemble de facteurs génétiques et environnementaux sont impliqués dans cette maladie complexe. Dans le cadre de mes études doctorales, je me suis intéressée à la composante génétique associée au risque de cancer du sein chez les femmes dans la population générale ainsi qu’à la modification du risque pour ce cancer chez des porteuses de mutations des gènes BRCA1 et BRCA2. Actuellement, environ la moitié de cette composante génétique est expliquée par une combinaison d'allèles à pénétrance faible, moyenne ou élevée. En outre, de récentes études ont démontré l'implication majeure de certains facteurs génétiques dans la modification du risque de cancer du sein chez des porteuses de mutations de BRCA1 et BRCA2. Dans le cadre de ce projet, nous avons étudié l’impact potentiel de certains variants génétiques dans les régions régulatrices de différents gènes et évalué leurs associations avec le risque de cancer du sein. Le projet a été divisé en deux parties : tout d'abord, nous avons évalué l'association directe entre les variants associés avec l’expression allélique différentielle et le risque de cancer du sein, afin d'identifier de nouveaux locus de susceptibilité à ce cancer. En second lieu, nous avons évalué l'impact sur l’expression génique de variants caractérisés au sein des régions promotrices de certains gènes sélectionnés, pour ensuite évaluer l’impact de ces variants sur l’expression génique. En résumé, la première partie de ce projet a conduit à l'identification d'un nouveau locus de faible pénétrance associés au risque de cancer du sein sur le locus 4q21 (rs11099601, odds ratio=1.05, p = 6.4 x 10-6), et deux nouveaux locus (11q22.3 et BRCA1- rs16942) associés avec la modification du risque de cancer du sein chez les porteuses de mutations du gène BRCA1. La seconde partie du projet a permis l'identification de nouveaux variants fonctionnels situés dans les régions promotrices des gènes ESR1, ESR2, FOXA1, RAP80, NBN et CDC7. D’autres études d’association dans de plus large cohorte ainsi que d’autres analyses fonctionnelles seront nécessaires pour confimer ces résultats, ce qui permettra de les inclure dans les nouveaux outils de prédiction de risque et ainsi assurer une estimation plus précise du risque de cancer du sein.
Breast cancer is the most common malignancy in women. A set of environmental and genetic factors are involved in this complex disease. This project focused on the genetic components of breast cancer susceptibility and breast cancer risk modification in BRCA1 and BRCA2 mutation carriers. Currently, about half of the inherited susceptibility to breast cancer can be imputed to a combination of high-, intermediate-, and low-risk alleles. Thus, many as yet unknown susceptibility loci remain to be identified. Moreover, recent studies have provided evidence for the involvement of genetic risk factors that might considerably modify the risk of developing breast cancer in BRCA1 and BRCA2 mutation carriers. Furthermore, genome-wide association studies have shown that several genetic variants within non-coding gene regions are associated with breast cancer risk. In this project, we focused on regulatory gene variants and their association with breast cancer risk. The project was divided in two parts. In the first section, we evaluated the direct association between single-nucleotide polymorphisms associated with differential allelic expression and breast cancer risk in order to identify new loci of breast cancer susceptibility. In the second part, we evaluated the functional impact on gene expression of variants identified within the promoter regions of selected candidate genes and then, characterize the functional impact of these variants. In summary, the first part of this project has led to the identification of a new low-penetrance locus associated with breast cancer risk on the 4q21 locus (rs11099601; odds ratio=1.05, p= 6.4 x 10-6), and two new modifiers of breast cancer risk in BRCA1 mutations carriers (11q22.3 locus and the wild type allele of BRCA1). The second part of the project allowed us to describe new functional variants within the promoters of the selected breast cancer gene candidates. Other association studies in larger cohorts and further functional analysis will be required to confirm these results, which will allow their inclusion in breast cancer risk prediction tools and thus ensure a more accurate estimation of breast cancer risk.

Style APA, Harvard, Vancouver, ISO itp.

33

Gerber, Jaclyn. "Cytochrome P450 polymorphisms : relevance in two South African disease populations". Thesis, Stellenbosch : Stellenbosch University, 2003. http://hdl.handle.net/10019.1/53345.

Pełny tekst źródła

Streszczenie:

Thesis (MSc)--Stellenbosch University, 2003.
ENGLISH ABSTRACT: With knowledge of the human genome increasing constantly we are continually faced with new and potentially groundbreaking methods for managing, treating and/or identifying diseases and predisposition to diseases and conditions at a genetic level. The human cytochrome P450 (CYP) super-family of genes code for enzymes that can participate in metabolism of drugs and foreign chemicals and in steroid synthesis and metabolism. Mutations in these genes may contribute to clinically relevant diseases. In this study, the effects of mutations within four CYP genes were evaluated in two South African disease groups - variegate porphyria and breast cancer. Variegate porphyria (VP) has an unusually high incidence in South Africa due to the R59W founder mutation in the protoporphyrinogen oxidase (PPOX) gene that causes a disruption in the haem biosynthetic pathway. VP presents with variable clinical symptoms and has a relatively low penetrance. It is expected that environmental factors and modifier genes play a role in the clinical expression of VP. CYP genes are implicated as candidate modifier genes for the expression of VP due to the function they have in metabolising many drugs contraindicated in porphyria patients, and the necessity of haem binding to the apoprotein to produce a functional CYP enzyme. This is the first study to investigate CYPs as possible modifier genes for VP clinical expression. Six CYP polymorphisms (CYPIAlml, CYPIAlm2, CYPIA2 - 734 C>A, CYPIBI 8372 A>C, CYP2D6*3, CYP2D6*4), associated with four CYP loci, were genotyped in a VP population and a suitable control population. The results observed are suggestive of CYPIAlml and CYPIBI playing a role as modifiers for the clinical expression of VP as they were significantly associated (PA and CYPIBI 8372 A>C). This represents the first investigation of the potential role of CYPs as breast cancer risk modifiers in the two South African populations. Significant differences were observed (PC polymorphism in the population of mixed ancestry. Vast differences in allele frequencies were also observed between the two groups of breast cancer populations. These results emphasize the importance of population-based risk assessment when genetic testing and counselling for complex disease susceptibility is offered. The results of this study provide the first evidence suggesting a role for CYPs in modifying the clinical expression of VP and in acting as risk factors for developing breast cancer in a South African population.
AFRIKAANSE OPSOMMING: Met die konstante toename van kennis oor die mensgenoom kom ons voortdurend te staan voor nuwe metodes vir die beheer, behandeling en/of identifikasie van siektes en vatbaarheid vir siektes op 'n genetiese vlak. Die mens sitochroom P450 geensuperfamilie kodeer vir ensieme betrokke in die metabolisme van medisyne en ander chemiese stowwe en steroïed-sintese en -metabolisme. Mutasies in hierdie gene kan 'n bydrae lewer tot kliniese relevante siektes. In hierdie studie is die effek van mutasies in vier sitochroom gene bestudeer in twee Suid-Afrikaanse siekte groepe, variegate porfirie en borskanker. Variegate porfirie (VP) het 'n besonderse hoë frekwensie in Suid-Afrika as gevolg van die R59W stigter-mutasie in die protoporfirinogeen oksidase (PPOX) geen. Hierdie mutasie lei tot 'n versteuring in die heem biosintese padweg. VP presenteer met variërende kliniese simptome en het 'n betreklike lae penetrasie. Daar word vermoed dat omgewingsfaktore en kandidaat modifiserende gene 'n rol speel in die kliniese beeld van VP. Sitochroom P450 gene is geïdentifiseer as kandidaat modifiserende gene as gevolg van hulle rol in die metabolisme van verbode medikasie vir porfirie pasiënte, asook die binding van heem aan die apoproteïen wat noodsaaklik is vir die produksie van funksionele sitochroom P450 ensiem. Hierdie is die eerste studie wat sitochroom P450 gene as moontlike modifiserende gene vir die kliniese uitdrukking van VP ondersoek. Ses sitochroom P450 polimorfismes (CYPIAlml, CYPIAlm2, CYPIA2 -734 C>A, CYPIBI 8372 A>C, CYP2D6*3, CYP2D6*4) is ondersoek in beide 'n VP populasie en 'n geskikte kontrole populasie. Die resultate suggereer 'n rol vir CYPIAlml en CYPIBI in die modifisering van die kliniese uitdrukking van VP aangesien hulle betekenisvolle assosiasie (PA, CYPIBI 8372 A>C). Hierdie studie verteenwordig die eerste ondersoek na die potensiële rol van sitochroom P450s as risiko-modifiserende faktore vir borskanker in die twee populasies. Betekenisvolle verskille (PC polimorfisme in die gemengde herkoms populasie. Beduidende verskille in alleel frekwensies is ook waargeneem tussen die twee borskanker populasies. Hierdie resultate beklemtoon die belangrikheid van populasie gebaseerde risiko-beraming wanneer genetiese toetse en voorligting vir komplekse siekte-vatbaarheid aangebied word. Die resultate van hierdie studie bied die eerste getuienis dat sitochroom P450s 'n rol kan speel in die modifisering van die kliniese beeld van VP en ook kan optree as as risiko faktore vir die ontwikkeling van borskanker in 'n Suid-Afrikaanse populasie.

Style APA, Harvard, Vancouver, ISO itp.

34

Dedeurwaerder, Sarah. "Biological and clinical relevance of epigenetic modifications in human breast cancers". Doctoral thesis, Universite Libre de Bruxelles, 2011. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/209896.

Pełny tekst źródła

Streszczenie:

It is increasingly recognized by the scientific community that the field of epigenetics is a key step for a better understanding of human biology in both normal and pathological states. Its implication in cancer, and in particular in breast cancer, is now well accepted. Breast cancer, responsible for more than 450,000 deaths worldwide yearly, is a heterogenous disease at the histological and clinical levels as well as at the molecular level. Despite considerable efforts to develop new treatments and improve patient management, patients with a same “profile” of breast cancer can respond differently to therapies and have completely different clinical outcomes. There is therefore a critical need to improve our understanding of breast cancer biology and diversity, in order to find new markers that should provide a better management of patients and the development of new therapies. An increasing number of biologists, pathologists as well as clinicians are currently working towards these goals. During my PhD, we have conducted two studies in order to gain new insights into the contribution of epigenetics in breast cancer biology.

In the first study, by performing large genome-scale DNA methylation profiling of numerous breast tumors as well as of normal breast tissues, we first revealed the existence of six groups of breast tumors based on their DNA methylation profiles. Three of these groups showed a strong association with the basal-like, HER2 and luminal A breast cancer subtypes, previously identified by gene expression profiling. Interestingly, the three other groups were found to be a mixture of several gene expression-based subtypes, thus revealing the capacity of DNA methylation profiling to improve breast tumor taxonomy. Second, our study suggests that the establishment of DNA methylation patterns of breast tumors might help to determine their cell type of origin. Finally, we also showed that DNA methylation profiling can reflect the cell type composition of the tumor microenvironment and that a signature of T cell tumoral infiltration is associated with a good prognosis in particular categories of breast cancer patients.

In the second study, we revealed the clinical relevance of the KDM5 histone demethylases in breast cancer. The expression of these histone demethylases was deregulated in the analyzed breast tumors as well as in the pre-invasive samples as compared to normal breast samples. This suggests that KDM5 enzymes might be good markers for early diagnosis of breast cancer. Moreover, we showed a prognostic value of the KDM5C histone demethylase.

In conclusion, the above data should provide a better understanding of breast cancer biology and diversity, and this should bring new insights to improve breast cancer patient management.

Doctorat en Sciences biomédicales et pharmaceutiques
info:eu-repo/semantics/nonPublished

Style APA, Harvard, Vancouver, ISO itp.

35

Zheng, Ying. "The study of exosomes and microvesicles secreted from breast cancer cell lines". Thesis, University of St Andrews, 2012. http://hdl.handle.net/10023/3464.

Pełny tekst źródła

Streszczenie:

Exosomes are small secreted vesicles of endocytic origin with a size range of 50-150 nm. They are secreted by many cell types and display multiple biological functions including immune-activation, immune-suppression, antigen presentation, and the shuttling of mRNA and miRNA, as well as other cargo. We have characterised the exosomes secreted from two breast cancer cell lines, MDA-MB-231 and MCF7. Exosomes secreted from both cell lines display typical markers including ALIX, Tsg101, CD9 and CD63, and were capable of inducing apoptosis of the Jurkat T cell line, indicating the potential immune-suppressive function of such tumour-derived exosomes. To further investigate the biological potential of exosomes, we loaded purified exosomes with gene specific siRNAs using electroporation, and observed the targeted inhibition of both a known component of the exosome pathway, Rab27a, and also the arthritis associated gene ERAP1, demonstrating the potential novel use of exosomes as therapeutic gene delivery vectors. We have also shown that exosomes derived from MDA-MB-231 cells and the parental cells have different lipid composition, as analysed by lipidomics study. Nanoparticle tracking analysis (NTA), which allows the rapid detection of size and concentration of nanoparticles within the size range 10 nm-1000 nm was tested for its ability to accurately measure size and concentration of exosomes and microvesicles under different conditions. NTA was capable of detecting apoptotic vesicles induced by Taxol and Curcumin treatment. Immunodepletion was used to determine the percentage of CD9 and CD63 positive vesicles. Our data suggest that NTA is a useful technique for measuring size and concentration of exosomes and microvesicles. We hypothesized that NTA could assist in the screening of agents that interfere or promote exosome release. NTA was therefore used to detect increases in exosomes secretion induced by Tamoxifen and Thimerosal treatment, and to monitor the inhibition of exosome secretion from MDA-MB-231 breast cancer cells expressing inhibitory RNA targeted for Rab27a, a component of the exosome pathway. Increases in exosome release induced by Tamoxifen and Thimerosal was detected by NTA and a significant reduction in the release of exosomes by inhibition of Rab27a expression was also observed. Treatment with the known exosomal pathway inhibitor DMA also reduced exosome release, establishing the principle of NTA as a screening technique. We further compared the siRNA targeted cells for their ability to migrate, invade and form anchorage-independent colonies, which were all significantly reduced. Supplementation with MDA-MB-231 derived exosomes restored the ability to form colonies, suggesting exosomes may contribute to metastatic lesion formation. These data suggest that the exosomal pathway is a valid target to disrupt the behaviour of tumour cells and NTA can be used to monitor its activity.

Style APA, Harvard, Vancouver, ISO itp.

36

Gong, Chun, i 龚纯. "Regulation of estrogen receptor alpha expression by translation or degradation and the relevance to tamoxifen resistance in breastcancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B50534191.

Pełny tekst źródła

Streszczenie:

Breast cancer is one of the most prevalent cancers affecting women worldwide. In the breast, estrogen receptor alpha (ERα), upon binding with ligands, activates gene transcription and promotes cell growth and proliferation. Tamoxifen, a selective antagonist of ERα in breast, has been proved to be effective therapeutically. In spite of this, resistance remains a prominent issue and underlying mechanisms are not yet fully understood. Aberrant regulation of ER expression at genetic and transcriptional levels has been implicated as the mechanisms accounting for tamoxifen resistance. However, regulation of ERα expression at translational level including protein synthesis and degradation has not yet been characterized and its relevance to tamoxifen resistance has not been described. At level of protein synthesis, eukaryotic translation initiation factor 4E (eIF4E) selectively enhances the translation of 4E-sensitive mRNAs which contain long and complex 5’-untraslated regions (5’-UTR). eIF4E is often over-expressed in cancers. In silico analysis revealed that ERα contained a highly structured 5’-UTR similar to reported eIF4E-sensitive mRNAs, suggesting that ERα mRNA might be eIF4Esensitive. We showed by polysome fractionation and subsequent Q-PCR quantification that the ERα mRNAs were more actively translated in the cell line expressing higher levels of eIF4E. Consistently, transient transfection of eIF4E into an ERα-positive cell line resulted in enhanced protein expression of ERα. Moreover, subcelluar fractionation showed that eIF4E was bound with ERα mRNAs in the nucleus thus participating in transportation of mRNAs from the nucleus into the cytoplasm. Therefore, eIF4E could positively modulate protein synthesis of ERα by enhancing mRNA export in the nucleus as well as translation in the cytoplasm. Their positive correlation was validated in vivo using 106 Chinese breast cancer samples (Chi-square test, p=0.004). It was also found that elevated expression of eIF4E could mediate resistance to tamoxifen treatment and enhance cell survival. This could be due to enhanced expression of ERα or activation of PI3K/Akt pathway upon eIF4E over-expression. At the level of degradation, ERα is conjugated to poly-ubiquitin chains catalyzed by multiple enzymes and degraded by 26S polysomes. Carboxyl-terminus of Hsc70- interacting protein (CHIP) is an E3 enzyme specific for ERα degradation through interaction with ERα’s ligand-binding domain (LBD). Various splicing variants of ERα have been reported and implicated in tamoxifen resistance by interfering with functions of ERα wild type. Variants ERαΔ4, ERαΔ5, ERαΔ6/7 and ERαΔ7 with different degrees of truncation in their LBDs and differential expression were detected or reported in human breast cancers. Their interactions with CHIP may be different, resulting in variations in degradation. We found that the degradation of ERαΔ6/7 through ubiquitin-proteasome pathway was impaired whilst the degradation of other variants were less affected. This finding suggests that the binding site of CHIP to ERαmight be located within the peptide sequences encoded by exon6. Furthermore, as ERαΔ6/7 plays a dominant negative role in regulating functions of ERα wild type, aborted degradation of this variant may result in accumulation of this variant in the cell, inhibiting and inactivating ERα, making the cells refractile to tamoxifen treatment.
published_or_final_version
Pathology
Master
Master of Philosophy

Style APA, Harvard, Vancouver, ISO itp.

37

Lui, Lik-hang Eric, i 雷力恒. "Aberrant methylation of E-cadherin gene (ECAD) in invasive ductal breast carcinoma". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2005. http://hub.hku.hk/bib/B4501016X.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Keenan, Lisa A. "Family Environment, Social Support, and Psychological Distress of Women Seeking BRCA1 and BRCA2 Genetic Mutation Testing". Thesis, University of North Texas, 2002. https://digital.library.unt.edu/ark:/67531/metadc3240/.

Pełny tekst źródła

Streszczenie:

Shared characteristics and predictors of psychological distress are beginning to be identified in research on women seeking genetic testing for BRCA1 and BRCA2 gene mutations. This study further explored patterns of psychological distress for 51 community women waiting to receive such genetic test results. There was no significant relationship between psychological distress and family cancer history, personal cancer history, social support networks, and family environment. Women in this sample tended to rely more on females and relatives for support than males and friends. Social support satisfaction was not related to gender or number of relatives providing support. Thirty-four of the 36 women classified on the family environment type were from Personal Growth-Oriented families. Comparisons with normal and distressed family means revealed increased cohesion and expressiveness with decreased conflict, indicative of supportive family environments. Limitations and implications are discussed.

Style APA, Harvard, Vancouver, ISO itp.

39

Stieber, Daniel. "Analyse génétique de la sensibilité au cancer mammaire". Doctoral thesis, Universite Libre de Bruxelles, 2005. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/211000.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

Haibe-Kains, Benjamin. "Identification and assessment of gene signatures in human breast cancer". Doctoral thesis, Universite Libre de Bruxelles, 2009. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/210348.

Pełny tekst źródła

Streszczenie:

This thesis addresses the use of machine learning techniques to develop clinical diagnostic tools for breast cancer using molecular data. These tools are designed to assist physicians in their evaluation of the clinical outcome of breast cancer (referred to as prognosis).

The traditional approach to evaluating breast cancer prognosis is based on the assessment of clinico-pathologic factors known to be associated with breast cancer survival. These factors are used to make recommendations about whether further treatment is required after the removal of a tumor by surgery. Treatment such as chemotherapy depends on the estimation of patients' risk of relapse. Although current approaches do provide good prognostic assessment of breast cancer survival, clinicians are aware that there is still room for improvement in the accuracy of their prognostic estimations.

In the late nineties, new high throughput technologies such as the gene expression profiling through microarray technology emerged. Microarrays allowed scientists to analyze for the first time the expression of the whole human genome ("transcriptome"). It was hoped that the analysis of genome-wide molecular data would bring new insights into the critical, underlying biological mechanisms involved in breast cancer progression, as well as significantly improve prognostic prediction. However, the analysis of microarray data is a difficult task due to their intrinsic characteristics: (i) thousands of gene expressions are measured for only few samples; (ii) the measurements are usually "noisy"; and (iii) they are highly correlated due to gene co-expressions. Since traditional statistical methods were not adapted to these settings, machine learning methods were picked up as good candidates to overcome these difficulties. However, applying machine learning methods for microarray analysis involves numerous steps, and the results are prone to overfitting. Several authors have highlighted the major pitfalls of this process in the early publications, shedding new light on the promising but overoptimistic results.

Since 2002, large comparative studies have been conducted in order to identify the key characteristics of successful methods for class discovery and classification. Yet methods able to identify robust molecular signatures that can predict breast cancer prognosis have been lacking. To fill this important gap, this thesis presents an original methodology dealing specifically with the analysis of microarray and survival data in order to build prognostic models and provide an honest estimation of their performance. The approach used for signature extraction consists of a set of original methods for feature transformation, feature selection and prediction model building. A novel statistical framework is presented for performance assessment and comparison of risk prediction models.

In terms of applications, we show that these methods, used in combination with a priori biological knowledge of breast cancer and numerous public microarray datasets, have resulted in some important discoveries. In particular, the research presented here develops (i) a robust model for the identification of breast molecular subtypes and (ii) a new prognostic model that takes into account the molecular heterogeneity of breast cancers observed previously, in order to improve traditional clinical guidelines and state-of-the-art gene signatures./Cette thèse concerne le développement de techniques d'apprentissage (machine learning) afin de mettre au point de nouveaux outils cliniques basés sur des données moleculaires. Nous avons focalisé notre recherche sur le cancer du sein, un des cancers les plus fréquemment diagnostiqués. Ces outils sont développés dans le but d'aider les médecins dans leur évaluation du devenir clinique des patients cancéreux (cf. le pronostique).

Les approches traditionnelles d'évaluation du pronostique d'un patient cancéreux se base sur des critères clinico-pathologiques connus pour être prédictifs de la survie. Cette évaluation permet aux médecins de décider si un traitement est nécessaire après l'extraction de la tumeur. Bien que les outils d'évaluation traditionnels sont d'une aide importante, les cliniciens sont conscients de la nécessité d'améliorer de tels outils.

Dans les années 90, de nouvelles technologies à haut-débit, telles que le profilage de l'expression génique par biopuces à ADN (microarrays), ont été mises au point afin de permettre aux scientifiques d'analyser l'expression de l'entièreté du génôme de cellules cancéreuses. Ce nouveau type de données moléculaires porte l'espoir d'améliorer les outils pronostiques traditionnels et d'approfondir nos connaissances concernant la génèse du cancer du sein. Cependant ces données sont extrêmement difficiles à analyser à cause (i) de leur haute dimensionalité (plusieurs dizaines de milliers de gènes pour seulement quelques centaines d'expériences); (ii) du bruit important dans les mesures; (iii) de la collinéarité entre les mesures dûe à la co-expression des gènes.

Depuis 2002, des études comparatives à grande échelle ont permis d'identifier les méthodes performantes pour l'analyse de groupements et la classification de données microarray, négligeant l'analyse de survie pertinente pour le pronostique dans le cancer du sein. Pour pallier ce manque, cette thèse présente une méthodologie originale adaptée à l'analyse de données microarray et de survie afin de construire des modèles pronostiques performants et robustes.

En termes d'applications, nous montrons que cette méthodologie, utilisée en combinaison avec des connaissances biologiques a priori et de nombreux ensembles de données publiques, a permis d'importantes découvertes. En particulier, il résulte de la recherche presentée dans cette thèse, le développement d'un modèle robuste d'identification des sous-types moléculaires du cancer du sein et de plusieurs signatures géniques améliorant significativement l'état de l'art au niveau pronostique.
Doctorat en Sciences
info:eu-repo/semantics/nonPublished

Style APA, Harvard, Vancouver, ISO itp.

41

Feinstein, Carla Fran. "Dying to Know". PDXScholar, 2010. https://pdxscholar.library.pdx.edu/open_access_etds/1318.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

Piessevaux, Géraldine. "Analyse génétique du cancer du mammaire chez le rat: étude de lignées congéniques". Doctoral thesis, Universite Libre de Bruxelles, 2008. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/210376.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Lodder, Lidewij Nathanja. "Dealing with the risk for hereditary breast and ovarian cancer a prospective study on psychological consequences of choices on genetic testing, surveillance and prophylactic surgery /". [S.l.] : Rotterdam : [The Author] ; Erasmus University [Host], 2001. http://hdl.handle.net/1765/13815.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

Equeter, Carole. "Analyse des profils d'expression génique des lymphocytes T CD4+ chez les patientes atteintes d'un cancer du sein". Doctoral thesis, Universite Libre de Bruxelles, 2009. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/210249.

Pełny tekst źródła

Streszczenie:

De nombreux travaux ont démontré la modulation, par les tumeurs, de certaines fonctions des cellules du système immunitaire. Dans le cadre de notre travail, nous avons étudié les lymphocytes T CD4+, cellules clefs de la réponse immune spécifique, chez des patientes atteintes d’un cancer du sein.

Sur base de l’établissement des profils d’expression génique des lymphocytes T infiltrant les tumeurs, nous avons dérivé la « tumor-infiltrating CD4+ signature » (TICD4S) composée de 61 gènes immuns et qui reflète l’état d’activation immunitaire. Cette signature présente une valeur prédictive chez les patientes porteuses de tumeurs ERBB2-positives et ER-négative/PR-négative/ERBB2-négative: une plus forte expression de ces gènes est associée à une meilleure survie.

Nous avons également étudié conjointement les profils géniques établis au départ des lymphocytes T CD4+ de la tumeur, du ganglion axillaire et du sang de dix patientes. Nous avons constaté que ces profils d’expression génique des TIL CD4+ diffèrent selon le statut ER de la tumeur qu’ils infiltrent. Les lymphocytes T ganglionnaires CD4+ subissent également les effets de la masse tumorale et, tout comme les TIL, sont moins activés chez les patientes porteuses de tumeurs ER-négatives. Par contre, les lymphocytes T sanguins semblent subir dans une moindre mesure les effets de la tumeur et peu de différences ont été notées par rapport à leurs homologues isolés chez des donneuses saines.\
Doctorat en Sciences
info:eu-repo/semantics/nonPublished

Style APA, Harvard, Vancouver, ISO itp.

45

González-Zuloeta, Ladd Angela Maria. "Genetic determinants of breast cancer". [S.l.] : Rotterdam : [The Author] ; Erasmus University [Host], 2007. http://hdl.handle.net/1765/10525.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Hussien, M. "Folate status, genetic damage and breast cancer". Thesis, Queen's University Belfast, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.269044.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

Gentile, Massimiliano. "Genetic alterations in early onset breast cancer /". Linköping : Univ, 2001. http://www.bibl.liu.se/liupubl/disp/disp2001/med686s.pdf.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Wedrén, Sara. "Genetic susceptibility to breast and endometrial cancer /". Stockholm, 2004. http://diss.kib.ki.se/2004/91-7140-053-2/.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Ford, Deborah. "Genetic epidemiology of breast and ovarian cancer". Thesis, Institute of Cancer Research (University Of London), 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.367527.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

50

Mackay, James. "Molecular genetic studies in human breast cancer". Thesis, University of Edinburgh, 1989. http://hdl.handle.net/1842/19076.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Rozprawy doktorskie na temat „Breast – Cancer – Genetic aspects”

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych